NeurAxis, Inc.NRXS
Key ratios
FCF / Sales
-181.1%2025
2024
-228.1%2023
-273.4%
Net margin
-144.4%TTM
2025
-218.6%
ROA
-56.2%TTM
2025
-80.6%2024
-169.9%2023
-418.6%
ROE
-139.8%TTM
2025
-285.4%2024
-2480.5%
Revenue growth
32.9%2025
2024
9.2%2023
-8.4%
Recent news
NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 Million Additional Covered Lives
NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth
Track NRXS in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer